SCHEMBL696193

SCHEMBL696193

COC(=O)C1(Oc2ccc(Cl)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.43
ATF4 P18848 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MMP13 P45452 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAP4K4 O95819 1/20 0.39
PTGS2 P35354 3/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C19 P33261 1/20 0.39
PPARA Q07869 1/20 0.39
HSD11B1 P28845 1/20 0.38
HSD11B2 P80365 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LIPE Q05469 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28596203 0.92 HPGD (0.57) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL1712603 0.84 GAA (0.44) SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL15897779 0.83 RAB9A (0.43) HPGDALDH1A1SMN1; SMN2MMP13MEN1
SCHEMBL24724755 0.81 MAPT (0.48) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL24724757 0.81 CTSK (0.40) ALDH1A1SMN1; SMN2MEN1KMT2APTGS2
SCHEMBL697540 0.80 MAP4K4 (0.53) HPGDATF4MMP13MEN1KMT2A
SCHEMBL28594375 0.79 KMT2A (0.43) HPGDALDH1A1KMT2AMAPTPPARA
SCHEMBL28586027 0.79 GRM5 (0.43) HPGDALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL24724754 0.79 CTSK (0.41) ALDH1A1SMN1; SMN2MEN1KMT2APTGS2
SCHEMBL28590421 0.78 SRD5A2 (0.48) HPGDALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680343-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-21 EP disclosed
WO-2024192415-A1 PROTEIN-PROTEIN INTERACTION STABILIZERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-09-19 WO disclosed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
CN-102405211-A Proline derivatives as cathepsin inhibitors HOFFMANN LA ROCHE 2012-04-04 CN disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 HPGD 346/4885ATF4 783/4885ALDH1A1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.